Zenarestat
Zenarestat Basic information
- Product Name:
- Zenarestat
- Synonyms:
-
- 3-(2-Fluoro-4-bromobenzyl)-7-chloro-2,4(1H,3H)-dioxoquinazoline-1-acetic acid
- 3-[(4-Bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid
- FK-366
- Zenarestat
- FR 74366
- 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid
- [3-(4-Bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydro-1(2H)- quinazolinyl]acetic acid
- 1(2H)-Quinazolineacetic acid, 3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-
- CAS:
- 112733-06-9
- MF:
- C17H11BrClFN2O4
- MW:
- 441.639
- Mol File:
- 112733-06-9.mol
Zenarestat Chemical Properties
- Melting point:
- 223-224°
- Boiling point:
- 624.4±65.0 °C(Predicted)
- Density
- 1.737
- solubility
- DMSO : 100 mg/mL (226.43 mM; Need ultrasonic)
- pka
- 3.76±0.10(Predicted)
- form
- Solid
- color
- White to off-white
Zenarestat Usage And Synthesis
Originator
FK 366 ,Fujisawa Pharmaceutical
Uses
Treatment of diabetic neuropathy (aldose reductase inhibitor).
Manufacturing Process
To a solution of 4-bromo-2-fluorobenzylamine and triethylamine in chloroform
was added dropwise a solution of 4-chloro-2-nitrobenzoyl chloride in
chloroform at 0°C with stirring and the mixture was stirred at the same
temperature for 1 h. The reaction mixture was washed in turn with diluted
aqueous hydrochloric acid and water, and then dried. Evaporation of the
solvent followed by recrystallization from diethyl ether gave N-(4-bromo-2-
fluorobenzyl)-4-chloro-2-nitrobenzamide.
A mixture of N-(4-bromo-2-fluorobenzyl)-4-chloro-2-nitrobenzamide and iron
(1.45 g) in acetic acid (66 ml) was stirred at 100°C for 30 min. After cooling,
iron was filtered off. The filtrate was evaporated to give a residue, which was
made alkaline with aqueous 1 N sodium hydroxide and extracted with ethyl
acetate. The extract was washed with water and dried. Removal of the solvent
gave 2-amino-N-(4-bromo-2-fluorobenzyl)-4-chlorobenzamide.
2-Amino-N-(4-bromo-2-fluorobenzyl)-4-chlorobenzamide and N,N'-
carbonyldiimidazole were dissolved in dioxane (50 ml). The solution was
evaporated to give a residue, which was stirred at 150°C for 30 min. After
cooling, the precipitates were collected by filtration and washed with ethanol
to give 3-(4-bromo-2-fluorobenzyl)-7-chloro-1,2,3,4-tetrahydro-2,4-
dioxoquinazoline; melting point >280°C.
To a suspension of 3-(4-bromo-2-fluorobenzyl)-7-chloro-1,2,3,4-tetrahydro-
2,4-dioxoquinazoline in N,N-dimethylformamide was added sodium hydride
(60% in mineral oil) with stirring at 0°C and the mixture was stirred for 15
min at the same temperature. To this mixture was added ethyl bromoacetate
and the mixture was stirred for 1 h at room temperature. The reaction
mixture was poured into diluted hydrochloric acid and extracted with ethyl
acetate. The extract was washed with brine, dried and evaporated to give a
residue. Thus obtained product was purified by recrystallization from isopropyl
ether to give 2-[3-(4-bromo-2-fluorobenzyl)-7-chloro-1,2,3,4-tetrahydro-2,4-
dioxoquinazolin-1-yl]acetic acid melting point 223°-224°C.
Therapeutic Function
Aldose reductase inhibitor
ZenarestatSupplier
- Tel
- 18871490254
- linda@hubeijusheng.com
- Tel
- +8618523575427
- sales@conier.com
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Tel
- 021-59167510 18117107507
- vip@med-life.cn
- Tel
- 15002134094
- marketing@targetmol.cn
Zenarestat(112733-06-9)Related Product Information
- 1,3-dimethyl-2,4-(1H,3H)-quinazolinedione
- 7-chloroquinazoline-2,4(1H,3H)-dione
- 4-Bromo-2-fluorobenzylamine hydrochloride
- Zenarestat
- 5-Chloro-2-methylphenylurea
- BENZYL-(2-FLUORO-BENZYL)-AMINE
- 2-[(3-chlorophenyl)amino]acetic acid
- 3-METHYLQUINAZOLINE-2,4(1H,3H)-DIONE
- CHEMBRDG-BB 5937785
- 2-amino-4-chlorobenzamide
- 4-BROMO-2-FLUOROBENZYLAMINE
- 3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE